Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 12/20 | 0.53 |
| ▸ | PTGER2 | P43116 | 12/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4077776 | 0.94 | PTGER4 (0.55) | PTGER4PTGER2ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL4087561 | 0.90 | PTGER4 (0.60) | PTGER4PTGER2PTGER3 | |
| SCHEMBL4077733 | 0.87 | ALDH1A1 (0.41) | PTGER4PTGER2ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL4077410 | 0.86 | PTGER4 (0.57) | PTGER4PTGER2ALDH1A1SMN1; SMN2PTGER3 | |
| SCHEMBL4081966 | 0.85 | PTGER4 (0.62) | PTGER4PTGER2PTGER3 | |
| SCHEMBL4077676 | 0.84 | PTGER4 (0.61) | PTGER4PTGER2ALDH1A1SMN1; SMN2PTGER3 | |
| SCHEMBL4087547 | 0.81 | PTGER4 (0.58) | PTGER4PTGER2PTGER3 | |
| SCHEMBL4080279 | 0.81 | ALDH1A1 (0.40) | PTGER4PTGER2ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL4077758 | 0.80 | PTGER4 (0.64) | PTGER4PTGER2PTGER3 | |
| SCHEMBL4080468 | 0.79 | PTGER4 (0.60) | PTGER4PTGER2SMN1; SMN2MAPTPTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1847533-B1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-7531533-B2 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-1847533-A1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | WNT1, CYP11B2, CYP11B1 | PTGER4 33/4885PTGER2 39/4885ALDH1A1 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.